Procena depresije kod bolesnika sa glaukomom otvorenog ugla
Sažetak
Uvod/Cilj. Depresija može biti izazvana nekom životnom situacijom. Cilj rada bio je da se utvrdi uticaj oštećenja izazvanog glaukomom na učestalost pojave depresije, kao i da se utvrde faktori rizika za nastanak depresije kod pacijenata sa glaukomom otvorenog ugla (GOU). Metode. Studija je dizajnirana kao klinička, opservaciona studija (studija preseka). Istraživanje je obuhvatilo 150 bolesnika oba pola, starijih od 40 godina, sa potvrđenom dijagnozom GOU. Obavljeni su detaljni oftalmološki pregledi, a anamnestički i sociodemografski podaci su prikupljeni putem upitnika. Kao instrument merenja za procenu depresije, korišćena je skala Beck Depression Inventory-II. Rezultati. Potvrđena je visoka (51,3%) prevalenca simptoma depresije kod bolesnika sa GOU. Od depresije su češće obolevale žene, osobe sa nižom mesečnom zaradom i nižim vrednostima srednje devijacije indeksa vidnog polja. Kod bolesnika sa uznapredovalim glaukomom, uočena je značajno viša učestalost simptoma depresije. Zaključak. Zbog visoke prevalencije simptoma depresije, važno je uvođenje multidisciplinarnog pristupa lečenju od strane oftalmologa i psihijatra. Otkrivanje i lečenje simptoma depresije u ranoj fazi bolesti dovodi do značajnog smanjenja troškova lečenja i onesposobljenosti bolesnika.
Reference
Tahir A, Ahmed MW, Khan S, Zafar O, Sarfraz MH, Tarar MS. Depression and anxiety in glaucoma patients using mono drug therapy vs polydrug therapy. J Rawalpindi Med Coll 2023; 27(2).
Rulli E, Quaranta L, Riva I, Poli D, Hollander L, Galli F, et al. Visual field loss and vision-related quality of life in the Ital-ian Primary Open Angle Glaucoma. Scientific Reports 2018; 8(1): 619.
Riva I, Legramandi L, Katsanos A, Oddone F, Rulli E, Roberti G, et al. Influence of sociodemographic factors on disease char-acteristics and vision-related quality of life in primary open-angle glaucoma patients: the Italian Primary Open Angle Glaucoma Study (IPOAGS). J Glaucoma, 2018; 27(9): 776–84.
Garcia-Villanueva C, Milla E, Bolarin JM, García-Medina JJ, Cruz-Espinosa J, Benítez-Del-Castillo J, et al. Impact of System-ic Comorbidities on Ocular Hypertension and Open-Angle Glaucoma, in a Population from Spain and Portugal. J Clin Med 2022; 11(19): 5649.
Lim NC, Fan CH, Yong MK, Wong EP, YipLW. Assessment of Depression, Anxiety, and Quality of Life in Singaporean Pa-tients With Glaucoma. J Glaucoma 2016; 25(7): 605–12.
Stamatiou ME, Kazantzis D, Theodossiadis P, Chatziralli I. De-pression in glaucoma patients: A review of the literature. Semin Ophthalmol 2022; 37(1): 29–35.
Dayal A, Sodimalla KVK, Chelerkar V, Deshpande M. Preva-lence of Anxiety and Depression in Patients With Primary Glaucoma in Western India. J Glaucoma 2022; 31(1): 37–40.
Weiss GA, Goldich Y, Bartov E, Burgansky-Eliash Z. Compliance with eye care in glaucoma patients with comorbid depression. Isr Med Assoc J 2011; 13(12): 730–4.
Marić V, Božić M, Marjanović I, Stamenković M. Risk factors for depression in glaucoma patients. Serbian Archives of Medi-cine 2023; 151(5–6): 314–20.
Diniz-Filho A, Abe RY, Cho HJ, Baig S, Gracitelli CP, Medeiros FA. Fast Visual Field Progression Is Associated with Depres-sive Symptoms in Patients with Glaucoma. Ophthalmology 2016; 123(4): 754–9.
DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000; 160(14): 2101–7.
Gamiochipi-Arjona JE, Azses-Halabe Y, Tolosa-Tort P, Lazcano-Gómez G, Gonzalez-Salinas R, Turati-Acosta M, et al. Depres-sion and Medical Treatment Adherence in Mexican Patients With Glaucoma. J Glaucoma 2021; 30(3): 251–6.
Pappa C, Hyphantis T, Pappa S, Aspiotis M, Stefaniotou M, Kitsos G, et al. Psychiatric manifestations and personality traits as-sociated with compliance with glaucoma treatment. J Psycho-som Res 2006; 61(5): 609–17.
Bali SJ, Parmar T, Arora V, Ichhpujani P, Sagar R, Dada T. Evaluation of major depressive disorder in patients receiving chronic treatment with topical timolol. Ophthalmologica 2011; 226(3): 157–60.
Berchuck S, Jammal A, Mukherjee S, Somers T, Medeiros FA. Im-pact of anxiety and depression on progression to glaucoma among glaucoma suspects. Br J Ophthalmol 2021; 105(9): 1244–9.
Grujičič SŠ, Nikolić A. Cross-section studies: advantages and disadvantages. Health Care 2021; 50(4): 43–54.
European Glaucoma Society. Terminology and Guidelines for Glaucoma. 5th Ed. Savona, Italy: European Glaucoma Soci-ety; 2020.
Ng M, Sample PA, Pascual JP, Zangwill LM, Girkin CA, Lieb-mann JM, et al. Comparison of visual field severity classifica-tion systems for glaucoma. J Glaucoma 2012; 21(8): 551–61.
Novović Z, Mihić Lj, Tovilović S, Jovanović V, Biro M. Psychomet-ric characteristics of the Beck depression inventory on a Ser-bian student sample. Psychology 2011; 44(3), 225–43. (Ser-bian)
Timotijević I, Paunović V. Clinical assessment instruments in psychiatry. Beograd: Our book; 2010. p. 215.
Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988. p. 567.
Fisekovic Kremic MB. Factors associated with depression, anxie-ty and stress among patients with diabetes mellitus in primary health care: Many questions, few answers. Malays Fam Physi-cian 2020;15(3): 54–61.
Golubović S, Ilić T, Golubović B, Gajić M, Gajić Z. The occurrence of depressive symptoms in rheumatoid arthritis: a cross-sectional study. Vojnosanit Pregl 2023; 80(2): 128–35.
Tastan S, Iyigun E, Bayer A, Acikel C. Anxiety, depression, and quality of life in Turkish patients with glaucoma. Psychol Rep2010; 106(2): 343–57.
Skalicky S, Goldberg I. Depression and quality of life in pa-tients with glaucoma: a cross-sectional analysis using the Ger-iatric Depression Scale-15, assessment of function related to vision, and the Glaucoma Quality of Life-15. J Glaucoma 2008; 17(7): 546–51.
Holló G, Kóthy P, Géczy A, Vargha P. Personality traits, depres-sion, and objectively measured adherence to once-daily pros-taglandin analog medication in glaucoma. J Glaucoma 2009; 18(4): 288–92.
Wang SY, Singh K, Lin SC. Prevalence and predictors of de-pression among participants with glaucoma in a nationally representative population sample. Am J Ophthalmol 2012; 154(3): 436–44.e2.
Mabuchi F, Yoshimura K, Kashiwagi K, Shioe K, Yamagata Z, Kanba S, et al. High prevalence of anxiety and depression in patients with primary open-angle glaucoma. J Glaucoma 2008; 17(7): 552–7.
Verbeek DE, van Riezen J, de Boer RA, van Melle JP, de Jonge P. A review on the putative association between beta-blockers and depression. Heart Fail Clin 2011; 7(1): 89–99.
Cimolai N. Neuropsychiatric Adverse Events from Topical Ophthalmic Timolol. Clin Med Res 2019; 17(3–4): 90–6.
Shin DY, Jung KI, Park HYL, Park CK. The effect of anxiety and depression on progression of glaucoma. Sci Rep2021; 11(1): 1769.
Wändell P, Carlsson AC, Ljunggren G. Systemic diseases and their association with open-angle glaucoma in the population of Stockholm. Int Ophthalmol 2022; 42(5): 1481–9.
Tharmathurai S, Huwaina AS, Azhany Y, Razak AA, Che-Hamzah J, Fazilawati Q, et al. Quality of Life of Older Adults with Primary Open Angle Glaucoma using Bahasa Malaysia Version of Glaucoma Quality of Life 36 Questionnaire. Curr Aging Sci 2022; 15(2): 147–62.
Sesar I, Pušić-Sesar A, Jurišić D, Sesar A, Merdžo I, Ćavar I. Health-related quality of life in primary open-angle glaucoma patients. Acta Clin Croat 2020; 59(4): 623–31.